Judicialization of cannabidiol-based products in Brazil: an analysis from 2019 to 2022

• Autor(a) principal: Portela, Ronaldo
• Data de Publicação: 2023
• Outros Autores: Marques Mota, Daniel, José Gonçalves Ferreira, Paulo, Dias Lula, Mariana, Barcala Reis, Bruno, Nunes de Oliveira, Helian, Mariano Ruas, Cristina
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Cadernos de Saúde Pública
• Texto Completo: https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/8353
• topic: Canabidiol; Cannabis; Judicialização da Saúde; Avaliação de Tecnologias em Saúde; Cannabidiol; Cannabis; Judicialización de la Salud; Evaluación de la Tecnología Biomédica; Cannabidiol; Cannabis; Health’s Judicialization; Biomedical Technology Assessment

The study analyzed the lawsuits of patients who requested cannabidiol (CBD)-based products from the Brazilian Unified National Health System during the period from 2019 to 2022, describing sociodemographic, clinical, and legal characteristics. This is a cross-sectional study composed of the evaluation of the technical notes issued by the Center for Technical Support of the Judiciary (NatJus), which supports judicial decisions. The data were obtained from the e-NatJus system, of the Brazilian Ministry of Justice, using web scraping techniques. Logistic regression was used to estimate odds ratios with 95% confidence intervals. We analyzed 1,115 technical notes of the CBD plaintiffs, of which 54.7% of the male patients, with a mean age of 18.4 years, mostly from the South Region of the country (38.8%), and 49.6% sought treatment for epilepsy. Regarding the actions with favorable opinions, 28.8% had no scientific evidence, 26.5% pleaded for products without registration with the Brazilian Health Regulatory Agency, and 25.3% of those that had registration were not in compliance with the therapeutic indication. Patients from the Northeast Region had a chance of a favorable opinion increased by 3.0 times and those diagnosed with epilepsy by 2.3. The expert opinions that supported the magistrates for the judicial decisions regarding the demands of patients for cannabidiol-based products in Brazil were mostly in accordance with scientific evidence, denoting the importance of NatJus in the qualification of access to medicinal products in the country.